Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
Start Date
12/4/2023
Completion Date
4/1/2028
Summary
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
Detailed Description
A phase 2 prospective, interventional, non-randomized clinical trial design to investigate whether Restricted Spectrum Maps (RSM) attained from RSI-MRI (On-Q Prostate) improves PI-RADS accuracy compared to PI-RADS alone for the detection of clinically significant prostate cancer. Patients who have agreed to undergo an MRI and subsequent prostate needle biopsy will be approached to participate in the trial. The aims of the study are as follows: Goal 1. Validate RSI-MRI imaging biomarker performance using a prospective clinical trial. Goal 2. Calibrate the RSM values across different MRI scanner manufacturers. Goal 3. Translate RSI using a net clinical benefit model.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
Conditions
Locations
University of California, San Diego
La Jolla, California 92093
United States